申请人:AMURA THERAPEUTICS LTD
公开号:WO2009112839A1
公开(公告)日:2009-09-17
A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein: R3 is selected from cyclopentyl and cyclohexyl; R9 is a substituted 5 or 6-membered aryl or heteroaryl group or a 6,5- or 6,6-fused biaryl or heterobiaryl group. Compounds of formula (I) exhibit surprisingly high dual efficacies for human cathepsin S and K and are useful for the treatment of rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, cardiovascular diseases which exhibit significant damage and remodeling of extracellular matrix (ECM) and chronic pain.
本发明的第一个方面涉及公式(I)的化合物,或其药学上可接受的盐、水合物、复合物或前药,其中:R3选自环戊基和环己基;R9是取代的5或6成员芳基或杂芳基或6,5-或6,6-融合的双芳基或双杂芳基。公式(I)的化合物表现出对人类卡特普汀S和K的惊人双重功效,并可用于治疗类风湿性关节炎、骨关节炎、慢性阻塞性肺病(COPD)、动脉粥样硬化、心血管疾病,这些疾病表现出显着的细胞外基质(ECM)的损伤和重塑以及慢性疼痛。